Oncogenic activation of the phosphatidylinositol-3-kinase (PI3K), protein kinase B
(PKB/AKT), and mammalian target of rapamycin (mTOR) pathway is a frequent event in …

The introduction of second-generation androgen receptor antagonists (SG-ARAs) has
greatly impacted the treatment of metastatic prostate cancer, providing tolerable and …

In castration-resistant prostate cancer (CRPC), the loss of androgen receptor (AR)
dependence leads to clinically aggressive tumors with few therapeutic options. We used …

Prostate cancer is the second most common malignancy in men and androgen deprivation
therapy is the first‐line therapy. However, most cases will eventually develop castration …

Emerging scientific evidence indicates that inflammation is a critical component of tumor
promotion and progression. Most cancers originate from sites of chronic irritation, infections …

Purpose: Alterations in BRAF have been reported in 3% to 5% of prostate cancer, although
further characterization is lacking. Here, we describe the nature of BRAF alterations in …

Prostate cancer therapy for locally advanced and metastatic diseases includes androgen
deprivation therapy (ADT). Second-generation antiandrogens have a role in castration …

Background Inactivating missense mutations in the SPOP gene, encoding speckle‐type
poxvirus and zinc‐finger protein, are one of the most common genetic alterations in prostate …

The WNT pathway is a pleiotropic signaling pathway that controls developmental processes,
tissue homeostasis, and cancer. The WNT pathway is commonly mutated in many cancers …

Abstract B7-H3 (CD276) is an immune checkpoint overexpressed in prostate cancer with
minimal expression in normal tissues and associated with poor prognosis, making it an …